Perrigo gains FDA approval for Mucinex DM
Perrigo on Tuesday announced it has received final approval from the U.S. Food & Drug administration for the store brand OTC equivalent of Mucinex DM Maximum Strength (guaifenesin and dextromethorphan hydrobromide extended-release tablets, 1200 mg/60 mg).
“This final approval and upcoming launch is an important accomplishment for our OTC business,” Jeff Needham, executive vice president and president, Consumer Healthcare Americas, for Perrigo, said. “Key product launches like Perrigo’s store brand equivalent of Mucinex® DM Maximum Strength provide our customers and consumers with high quality, value alternatives in important treatment categories.”
Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive. Retail sales of the cough-cold product for the last 12 months were approximately $128 million as measured by IRI, Perrigo reported.
The company is finalizing plans to launch Perrigo’s wholly owned store brand equivalent of Mucinex DM Maximum Strength for the 2018 cough-cold season.
This product will be packaged and marketed as a retailer own brand and will provide consumers with a value alternative to Mucinex DM Maximum Strength.
Payfone and higi showcase upgraded digital experience
Payfone, a leading digital identity authentication network, and higi, a population health enablement company, on Monday unveiled a “Future of Healthcare Engagement Technology” experience at the Healthcare Information and Management Systems Society Conference in Las Vegas. The interactive demonstration showcased innovative capabilities from Payfone and higi that enable an elevated digital engagement experience for scalable population health solutions while protecting protected health information.
“We take pride in empowering enterprises across all sectors to deliver seamless, instant and secure experiences for their customers,” Rodger Desai, CEO of Payfone, said. “For the healthcare industry, that means allowing consumers to safely and conveniently access services like higi’s that can improve their health, while enforcing the highest levels of protected health information security. We are excited that our partnership with higi will allow us to use our advanced technology to better the lives and health of Americans.”
By rolling out Payfone’s secure passive identity authentication technology, which is also used by six of the top 10 banks in the United States, across higi’s 11,000 FDA-cleared self-screening kiosks across the U.S., higi will enable consumers to experience an easier way to measure and track their health data and share it with healthcare organizations and pharmacy retailers for immediate recommendations at a point of care.
Through the Payfone integration, individuals can use their cell phone to log in to a higi health station and initiate digital messaging from their health network.
“As consumers look for easier and more secure ways to manage their health data, we are thrilled to partner with Payfone and further our commitment to empowering consumers to be their healthiest while making it easier along the way,” Jeff Bennett, CEO of higi, said. “With the combined Payfone and higi capabilities, healthcare organizations can leverage a consumer-centric model to deploy scalable population health programs over a safe, secure and real-time digital platform.”
Illness rates still high across Texas, Walgreens Flu Index reports
Texas can’t seem to catch a break this flu season. Cities across the Lone Star State have ranked among the top 10 designated market areas with flu activity for the whole season, according to the weekly Walgreens Flu Index. For the week ended March 3, six Texas markets ranked among the top 10.
And while the Centers for DIsease Control and Prevention has been tracking illness gains in the Northeast, the three states with the greatest flu activity gains for this past week were Montana, Alaska and Oregon, Walgreens reported.
The top 10 markets with flu activity for the week ended March 3 were:
- Lincoln & Hastings-Kearney, Neb.;
- Harlingen-Weslaco-Brownsville-McAllen, Texas;
- Omaha, Neb.;
- Oklahoma City;
- El Paso, Texas (Las Cruces, N.M.);
- Waco-Temple-Bryan, Texas;
- Dallas-Ft. Worth, Texas;
- Columbia-Jefferson City, Mo.;
- Corpus Christi, Texas; and
- San Antonio.
Top 10 DMAs ranked by flu activity gains for the period were:
- Fresno-Visalia, Calif.;
- Anchorage, Alaska;
- Portland, Ore.;
- Bakersfield, Calif.;
- Sacramento-Stockton-Modesto, Calif.;
- San Francisco-Oakland-San Jose, Calif.;
- San Diego;
- Seattle-Tacoma, Wash.;
- Los Angeles; and
- Rochester, N.Y.
The Walgreens Flu Index is a weekly report developed to provide state- and market-specific information regarding flu activity, and ranks those states and markets experiencing the highest incidences of influenza across the country. The Flu Index provides insight by showing which cities or metropolitan areas are experiencing the most incidences of influenza each week based on Index methodology. The data does not measure actual levels or severity of flu activity.
The Walgreens Flu Index is compiled using weekly retail prescription data for antiviral medications used to treat influenza across Walgreens and Duane Reade locations nationwide, including Walgreens locations in Puerto Rico. The data is analyzed at state and geographic market levels to measure absolute impact and incremental change of antiviral medications on a per store average basis, and does not include markets in which Walgreens has fewer than 10 retail locations.